echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The dynamic adjustment mechanism of the medical insurance drug catalogue is basically established, and the decrease is not the determining factor

    The dynamic adjustment mechanism of the medical insurance drug catalogue is basically established, and the decrease is not the determining factor

    • Last Update: 2021-01-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, in 2020, the adjustment of the national medical insurance drug catalogue was officially completed, 119 kinds of drugs were added to the catalog, 29 kinds were transferred out.
    , the attention of the anti-cancer drug PD-1, 3 domestic enterprises all entered.
    reported that the negotiations, PD-1 and PD-L1 monoantigen drugs, including carelli-pearl monoantigen, including three drugs were shortlisted, involving a variety of diseases including lung cancer, liver cancer, melanoma, lymphoma and other malignancies, the average price drop of 78%.
    industry insiders said that from the patient burden situation, through negotiations to reduce prices and medical insurance reimbursement, it is expected that 2021 can be accumulated for patients to reduce the burden of about 28 billion yuan.
    the results of the fifth round of health care negotiations" negotiated the largest number of drugs, the most extensive areas of treatment.
    " on the negotiations, the State Health Insurance Administration, director of the Department of Medical Services Management Xiong Xianjun said so.
    the health care negotiations received a total of 2,155 corporate declarations, involving 1,267 drugs.
    , 722 drugs passed the formal examination, of which 704 were out-of-catalog drugs.
    , 23 (non-exclusive) drugs were transferred directly to the catalogue and 138 exclusive drugs were included in the negotiations.
    fact, this negotiation is not only the above 138 varieties, but also includes 24 already in the catalogue, the total number of drugs negotiated is 162.
    results showed that 119 successful negotiations had a total success rate of 73.46 per cent and an average price reduction of 50.64 per cent for successfully negotiated drugs.
    , through this catalog adjustment, a total of 119 drugs were added to the catalog, involving cancer, rare diseases, hepatitis, diabetes, rheumatoid immunity, cardiovascular, digestion and other 31 clinical treatment areas.
    total number of medicines in the adjusted National List of Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs (2020) is 2,800, of which 1,426 are Western medicines and 1,374 are Chinese medicines.
    of Chinese medicine tablets in the catalogue has not been adjusted, it is still 892.
    " success rate is still below last year's.
    " Xiong Xianjun said that the catalog adjustment adheres to the "basic" functional positioning, to ensure that health insurance fund expenditure can be controlled.
    In the process of catalog adjustment, adhere to the basic principle of "doing everything possible to protect the basic, always adhere to sustainability", through the transfer of clinically low-value drugs, negotiations to reduce the cost of drugs in the catalog significantly higher, special negotiations on the price of expired drugs, especially in recent years, concentrated procurement of "quantity for price" to further squeeze the price of drugs, to achieve "cage for birds", to ensure the basic balance of the fund.
    " has initially explored a path with Chinese characteristics to guide the return of drug costs to reasonable.
    " Xiong Xianjun said that through strategic purchase, make full use of drug access "price-for-volume" market mechanism, on the basis of scientific evaluation and measurement negotiations with enterprises, from passive buying to active bargaining, has produced greater results.
    It is estimated that through the monitoring of 114 negotiated drugs in the current catalogue, the average price reduction for health care negotiations from 2018 to 2020 will be more than 50%, and that, together with medical insurance reimbursements, the cumulative reduction in expenditures for insured patients will be 55.872 billion yuan compared with the pre-negotiation period.
    Xiong Xianjun pointed out that the next step will guide the local to do a good job of the new version of the catalog landing to implement the hanging network, March 1, 2021 in the country officially launched the new version of the catalog.
    , 17 cancer drugs negotiated in 2018 will be reimbursed under the original policy until February 28, 2021.
    catalog varieties will also open the way to negotiations economic orientation is also transmitted to the original catalog of drugs, the first attempt to the catalog of drugs price reduction negotiations, significantly improve the economy, evaluation experts according to the procedures to select the price or cost is high, the fund occupies more than 14 exclusive drugs for price reduction negotiations, these drugs are sold for more than 1 billion yuan a year.
    , all 14 drugs were successfully negotiated and kept in the catalogue, with an average price reduction of 43.46 per cent. the 14 exclusive varieties successfully negotiated by
    are the National Health Insurance Class B varieties, including the sodium butyl chloride injection of the stone medicine and the soft capsule of butyl benzene, the dorassin injection of methulphate of Hesco, the injection of Gringer Ingham with atipase, the oral solution of the blue herring of Yangzijiang, the 100-ring capsule of Hangzhou central and eastern China, etc.
    28, Stone Pharmaceutical Group announced that the company's butyl benzene softgels and sodium butyl chloride injections (commodity name: Ndip) health insurance payment standards will be adjusted by reference to the new catalog on March 1, 2021, lower than the current national minimum selling price of 55.6% and 51.3%, respectively.
    meters intranet data show that 14 exclusive varieties in 2019 China's public medical institutions terminal sales of more than 35 billion yuan, of which the stone medicine of butyl benzene softgels, Shandong Danhong Pharmaceutical's Danhong injection, Hangzhou, China and eastern China's 100-ling capsule sales of more than 3 billion yuan, Dansan polyphenols are as high as 4.1 billion yuan.
    In addition, Shenyang Sansheng recombinant human platelet-producing injection sales of 2.9 billion yuan, blue herring oral solution reached 2.8 billion yuan, Conlet injections, Kangai injections, acetate Gosherlin slow release implant sales also reached 2.6 billion yuan.
    Xiong Xianjun said the attempt to negotiate 14 drugs in the catalogue was only the beginning.
    he said that the previous drug into the health care list has not been negotiated, the price is higher than the current market, there is already a false high.
    and the lack of incentive and willingness to reduce prices for these drugs in recent years will continue to be followed by negotiations on the drugs listed in the catalogue.
    for the 29 drugs that were called out of the list, Xiong xianjun said, the main clinical value of the species is not high and replaceable, or by the drug regulatory department revoked the code as "zombie drugs" and other varieties.
    the transfer of these drugs, by experts repeatedly demonstrated, strictly in accordance with the procedures to determine, for more new drugs, good drugs into the catalog to make room.
    decline is not the determining factor Value is an important consideration Xiong Xianjun said, price decline is not the pursuit of negotiations, enterprises before the retail price pricing is more reasonable, health care negotiations price decline will naturally be small.
    for sky-high prices, Xiong said, taking into account the affordability of ordinary people for prices, as well as the affordability of health insurance after the inclusion of health insurance.
    Zheng Jie, an expert in the fund measurement group of the State Health Insurance Bureau and deputy director of the Medical Insurance Affairs Management Center of the Beijing Municipal Health Insurance Bureau, said that the pricing of drugs will fully exploit valuable information, including the competitive retail price of the drug in various domestic provinces and cities, as well as the international retail price, but also consider the impact of import tax rates, etc., through which the drug floor price will be determined.
    according to CCTV's Focus Interview, AstraZeneta's PD-1 product "Dvaliyu single resistance" second round offer of 2,159 yuan, by health care experts reminded "should go to a word to rely on."
    the second round of quotations, but in the fierce price competition, the offer still can not reach the floor price, negotiations had to be terminated.
    this also means that the winning bid of Baiji Shenzhou's Tyrelli Pearl Single Resistance, Junshi's Ripley Single Resistance, Hengrui's Karelli Pearl Single Resistance price will be lower.
    Yuankai, deputy director of the National Cancer Center and vice president of the Oncology Hospital of the Chinese Academy of Medical Sciences, said that in 2015 there were about 3.929 million cases of malignant tumors and about 2.338 million deaths.
    than 10,000 people are diagnosed with cancer every day, and 7.5 people are diagnosed with cancer every minute.
    cancer burden continues to rise compared with historical data.
    latest statistics show that malignant tumor deaths account for 23.91% of all deaths among residents, and the incidence and death of malignant tumors have been on the rise for more than a decade.
    Shi Yuankai said that through negotiations to reduce prices and medical insurance reimbursement of the dual role has greatly improved the access of patients, in recent years, the negotiation of cancer drugs in the international mainstream cancer treatment drugs, have clear clinical treatment of the adaptive disorders, has basically covered the major organ cancer. wang Rui, an analyst at
    Huajin Securities, said that the four domestic PD-1 single-anti-drug drugs have entered the health insurance catalog, the results of the negotiations are better than the market expected, it is expected that after this negotiation, the market share of domestic products is expected to further improve.
    health insurance catalog dynamic adjustment every year, innovative drugs into the speed of medical insurance greatly shortened, the normalization of medical insurance negotiations on the short-term price of products have a certain impact, but the price-for-volume into the medical insurance after the release effect is obvious.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.